Reply to Merli et al

Affiliations

¹ Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

Comment

Patrick R Harrington et al. Clin Infect Dis. 2016.

. 2016 Feb 15;62(4):528-9.

doi: 10.1093/cid/civ905. Epub 2015 Oct 27.

¹ Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Harrington PR, et al. Clin Infect Dis. 2015 Sep 15;61(6):974-7. doi: 10.1093/cid/civ419. Epub 2015 May 28. Clin Infect Dis. 2015. PMID: 26021996 Clinical Trial.
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.
Merli M, Messina E, Salpietro S, Lazzarin A, Uberti-Foppa C, Hasson H. Merli M, et al. Clin Infect Dis. 2016 Feb 15;62(4):527-8. doi: 10.1093/cid/civ902. Epub 2015 Oct 27. Clin Infect Dis. 2016. PMID: 26508514 No abstract available.